Skip to main content

Table 5 Results of the meta-analysis of the association between the ARLTS1 Trp149Stop, Pro131Leu, Ser99Ser and Leu132Leu variants and cancer risk

From: ARLTS1 polymorphism is associated with an increased risk of familial cancer: evidence from a meta-analysis

ARLTS1

Total

Familial

Sporadic

polymorphism

OR (95% CI) Ph

OR (95% CI) Ph

OR (95% CI) Ph

Trp149Stop

 GA vs. AA

1.11(0.66,1.86) 0.001

1.14(0.76,1.72) 0.843

0.65(0.38,1.10) 0.376

 GG + GA vs. AA

1.13(0.68,1.88) 0.001

1.20(0.80,1.79) 0.852

0.65(0.38,1.10) 0.376

Pro131Leu

 CT vs. CC

0.94(0.81,1.08) 0.624

1.14(0.76,1.72) 0.843

0.65(0.38,1.10) 0.376

 TT + CT vs. CC

0.93(0.81,1.07) 0.559

1.20(0.80,1.79) 0.852

0.65(0.38,1.10) 0.376

Ser99Ser

 AGvs. AA

1.04(0.73,1.48) 0.340

1.72(0.88,3.37) 0.943

1.35(0.40,1.79) 0.031

 GG + AGvs. AA

1.05(0.75,1.47) 0.366

1.67(0.93,3.02) 0.898

0.84(0.44,1.64) 0.043

Leu132Leu

 GC vs. GG

1.10(0.42,2.68) 0.674

1.13(0.26,4.90) 0.150

1.55(0.47,5.13) 0.000

  1. OR odds ratios, 95%CI, 95% confidence interval, P h, p-values for heterogeneity in Q-test